AUREKA LIMITED — Major Shareholding Notification 2021

Nov 21, 2021

605 page 1/2 15 July 2001

Form 605 Corporations Act 2001 Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme Navarre Minerals Limited ACN/ARSN 125 140 105

1. Details of substantial holder (1)

Name ACN/ARSN (if applicable)

Dr Stephen Garth Nordstrom

The holder ceased to be a substantial holder on 19/11/2021 The previous notice was given to the company on 04/06/2021 The previous notice was dated 04/06/2021

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or

scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person’s votes affected
18/06/2021	Dr Stephen Garth Nordstrom	Acquisition on Market	$10,529.95	100,000 Fully paid ordinary shares	100,000
29/06/2021	Dr Stephen Garth Nordstrom	Share Purchase Plan	$30,000.00	300,000 Fully paid ordinary shares	300,000
28/07/2021	Dr Stephen Garth Nordstrom	Sale on Market	($2,920.05)	30,000 Fully paid ordinary shares	(30,000)
06/08/2021	Dr Stephen Garth Nordstrom	Dilutionary impact due to issue of shares by the Company	-	-	-
26/08/2021	Dr Stephen Garth Nordstrom	Dilutionary impact due to issue of shares by the Company	-	-	-
06/09/2021	Dr Stephen Garth Nordstrom	Sale on Market	($3,305.05)	35,000 Fully paid ordinary shares	(35,000)
27/09/2021	Dr Stephen Garth Nordstrom	Sale on Market	($2,980.05)	30,000 Fully paid ordinary shares	(30,000)
26/10/2021	Dr Stephen Garth Nordstrom	Sale on Market	(5,040.05)	55,000 Fully paid ordinary shares	(55,000)
09/11/2021	Dr Stephen Garth Nordstrom	Sale on Market	($2,230.05)	25,000 Fully paid ordinary shares	(25,000)
11/11/2021	Dr Stephen Garth Nordstrom	Sale on Market	($42,220.15)	615,500 Fully paid ordinary shares	(615,500)
12/11/2021	Dr Stephen Garth Nordstrom	Sale on Market	($28,025.05)	309,500 Fully paid ordinary shares	(309,500)
16/11/2021	Dr Stephen Garth Nordstrom	Sale on Market	($327,037.01)	3,804,020 Fully paid ordinary shares	(3,804,020)
17/11/2021	Dr Stephen Garth Nordstrom	Sale on Market	($96,330.51)	1,095,980 Fully paid ordinary shares	(1,095,980)
19/11/2021	Dr Stephen Garth Nordstrom	Dilutionary impact due to issue of shares by the Company	-	-	-

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN(if applicable)	Nature of association
N/A

Precedents 3735 v1 Bris_docs/8668061_1

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Dr Stephen Garth Nordstrom	Unit 1513, 28 Harbour Street, SydneyNSW 2000

Signature

print name sign here	Dr Stephen Garth Nordstrom capacity
	date 22/11/2021

Bris_docs/8668061_1

605 page 2/2 15 July 2001

DIRECTIONS

• (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.

• (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

• (3) See the definition of "associate" in section 9 of the Corporations Act 2001.

• (4) Include details of:

• (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

• (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

• See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

• (5) Details of the consideration must include any and all benefits, moneys and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

• (6) The voting shares of a company constitute one class unless divided into separate classes.

• (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Precedents 3735 v1 Bris_docs/8668061_1